Navigation Links
SanBio Announces Site Opening of Phase 1/2a Clinical Trial of Novel Cell Therapy in Stable Stroke Patients at University of Pittsburgh Medical Center
Date:9/20/2011

MOUNTAIN VIEW, Calif., Sept. 20, 2011 /PRNewswire/ -- SanBio, Inc., a leader in cell therapies for regenerative medicine, has announced the site initiation and opening of a Phase 1/2a clinical trial testing a novel cell therapy product, SB623, in patients suffering from disability resulting from ischemic stroke. The study is taking place at the University of Pittsburgh Medical Center. An additional study site is also open and recruiting patients at the Stanford University Medical Center in Palo Alto, CA.

SB623 has been shown to improve neurological behavior in preclinical models of stroke. In this study, safety and efficacy parameters will be evaluated, including improvements in motor function and cognitive status. The trial will evaluate 18 patients who have suffered an ischemic stroke within the past six to 24 months and have a motor neurological deficit.

"We are excited to be a part of this important new study offering a novel approach to therapy for patients suffering from ischemic stroke disability," said Douglas Kondziolka, MD, Peter J. Jannetta professor and vice chairman of neurological surgery at the University of Pittsburgh Medical Center (UPMC), and Principal Investigator of the study.

"Preclinical models have shown that SB623 restores function in animal models of stroke. With over seven million stroke victims in the U.S. today, we are eager to explore the potential of SB623 in patients who may otherwise be permanently disabled," said Lawrence Wechsler, MD, chair, department of neurology at UPMC.

"With two trial sites now open, our goal is to explore the potential of SB623 as a potential treatment for stroke disability as rapidly as possible," said Keita Mori, Co-CEO of SanBio. "SB623 represents a significant step forward in the development of regenerative therapies."

For more information on the SB623 trial, please visit www.strokeclinicaltrial.org.

About
'/>"/>

SOURCE SanBio, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Dainippon Sumitomo Pharma and SanBio Collaborate on Cell Therapy for Stroke Recovery
2. Stanford and SanBio Announce a Clinical Trial of Cell Therapy for Stroke Disability
3. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
4. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
5. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
6. Anesiva Announces Second Quarter 2008 Financial Results and Update
7. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
8. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
9. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
10. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
11. ThirdBiotech Announces Kemeta as Newest Sponsor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Based on the revenues gained from surgical imaging ... by four major players contributing to approximately 74% ... GE Healthcare (U.K.), Siemens AG (Germany), Philips (Netherlands), ... Copy at http://www.marketsandmarkets.com/Market-Reports/surgical-imaging-market-210534462.html , The leading ... its strong product portfolio, which includes its flagship ...
(Date:12/17/2014)... 2014 Achim Noack has been named ... Group. In this position, Noack will assist Jerry Stoller, ... develop marketing strategy and supervise global marketing management and ... has tremendous knowledge and experience in the crop protection ... experience and innovative thinking will be a great asset ...
(Date:12/17/2014)... 2014 Once more, EMAAR has ... packaged waste water treatment plant to phase one of ... (KAEC). Two years ago Bioshaft successfully supplied and operated ... two residential towers with an occupancy of 900 residences. ... million gallons per day and was signed on September ...
(Date:12/17/2014)... IN (PRWEB) December 17, 2014 ... Laboratory Excellence following its most recent COLA inspection. ... by COLA, a national healthcare accreditation organization. Accreditation ... standards of quality in day-to-day operations, demonstrate continued ... pass a rigorous on-site laboratory survey. ...
Breaking Biology Technology:Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4Achim Noack Joins Stoller Group as Global Vice President of Marketing and Administration 2Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2
... CAMBRIDGE, Mass., Nov. 4 Genstruct Inc., ... mechanisms, networks and,biomarkers to better develop novel ... has become a member of The Biomarker ... Foundation for the,National Institutes on Health (FNIH), ...
... in specialty biologics development, TORONTO and CHARLOTTETOWN, ... Inc. have agreed to partner in the development ... treatments, with a goal of,advancing the project to ... to add to its portfolio of biologic products., ...
... Help Children Reach Normal Height, PRINCETON, N.J., Nov. ... them from growing to a normal height now have ... [rDNA origin] injection) for the treatment of short stature ... catch-up growth by,age 2-4 years., The U.S. Food ...
Cached Biology Technology:Genstruct Added to The Biomarker Consortium's Rapidly Growing Roster of Industry Experts 2Genstruct Added to The Biomarker Consortium's Rapidly Growing Roster of Industry Experts 3Therapure Biopharma Inc. announces collaboration with BioVectra Inc. 2FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children 2FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children 3FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children 4FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children 5
(Date:11/18/2014)... -- The Secure Identity & Biometrics Association (SIBA) and ... formation of The Airport Entry and Exit Working ... Biometric Entry and Exit Solutions Framework for Airports ... BORDERPOL, the international non-profit organization that works directly ... border security, traveler and migration systems. ...
(Date:11/18/2014)... BETHESDA, Md. , Nov. 17, 2014 The ... European and U.S. regulatory agencies will speak and at least ... Quality Metrics Conference at the Omni Shoreham Hotel in ... is pleased once again to have significant support from the ... and Europe in our effort to ...
(Date:11/15/2014)... YORK , Nov. 13, 2014  While we may ... technology Doctor McCoy used in "Star Trek" to gain instant ... tools designed to work with smartphones and tablets for monitoring ... of the healthcare world. This may seem a tad Orwellian ... ready to adopt some of these technological opportunities into their ...
Breaking Biology News(10 mins):Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4
... to reach a compromise that outlaws reproductive cloning or ... potential abuse, prejudice and discrimination, according to authors of ... Institute of Advanced Studies ( www.ias.unu.edu ). A ... clone, coupled with freedom for nations to permit strictly ...
... University of Western Ontario is set to host Canadas ... Exercise Physiology (CSEP) Annual Scientific Conference. The four-day, ... November 17 at the London Convention Centre, for the ... of the countrys leading thinkers in the fields of ...
... 2007 Researchers at Childrens Hospital of Pittsburgh of UPMC ... study the effectiveness of oral insulin in preventing or delaying ... for the disease. The researchers want to determine if ... onset of type 1 diabetes in relatives of people who ...
Cached Biology News:Human clones: New U.N. analysis lays out world's choices 2Human clones: New U.N. analysis lays out world's choices 3Human clones: New U.N. analysis lays out world's choices 4Canadian Society of Exercise Physiology Annual Scientific Conference 2Children's Hospital studying drug with the potential to prevent/delay onset of type 1 diabetes 2
LIVE/DEAD® Sperm Viability Kit *200-1000 assays*...
in vitro Translation, Accessory Products...
... analysis of gene expression) technology ... Expression profiles generated by SAGE ... low-abundance transcripts making it possible ... I-SAGE Kit is designed to ...
Sheep Serum US Origin...
Biology Products: